New Drug Review

The FDA approved Lundbeck, Inc's Onfi (clobazam) as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients that are 2 years and older.

Gilead Sciences, Inc's Complera received approval from the FDA for use as a complete regimen for the treatment of HIV-1 infection in treatment-naïve adults.

The FDA approved a subcutaneous formulation of Bristol-Myers Squibb's Orencia (abatacept) for the treatment of moderately to severely active rheumatoid arthritis in adults.

The FDA approved Genentech's Zelboraf (vermurafenib) for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation.

The FDA has granted accelerated approval to Seattle Genetics, Inc’s Adcetris (brentuximab vedotin). Adcetris is indicated for the treatment of Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens in patients who are not candidates for ASCT.